Clinical Trial

HYALOBARRIER® GEL ENDO Versus no HYALOBARRIER® GEL ENDO Following Operative Hysteroscopy for Improving Reproductive Outcome in Women With Intrauterine Pathology Wishing to Become Pregnant

Study acronym: AGNOHSTIC
Unknown
View on ClinicalTrials.gov →
Summary
To compare the costs and effects of HYALOBARRIER® GEL ENDO versus no HYALOBARRIER® GEL ENDO for increasing the chance of conception leading to live birth measured at 30 weeks after randomization in women wishing to become pregnant after surgical removal of intrauterine pathology (endometrial polyps, fibroids with uterine cavity deformation, uterine septa, IUAs or RPOC after miscarriage) by hysteroscopy as an outpatient or in hospital treatment.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT03880435
Lead Sponsor University Hospital, Ghent
Collaborators: Belgium Health Care Knowledge Centre, Nordic Pharma SAS, Universitaire Ziekenhuizen KU Leuven, Universitair Ziekenhuis Brussel, Health, Innovation and Research Institute (HIRUZ) UZ Ghent, University of Liege, UCL Bruxelles, Jessa hospital, Hasselt
Conditions Infertility, Polyp Uterus, Myoma;Uterus, Adhesion, Hysteroscopy, Uterine Septum, Retained Products of Conception
Enrollment 419 participants
Start Date 2019-04-01
Primary Completion 2024-06-30 (estimated)
Study Completion 2025-05-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-30